ImmunoMet Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 9

Employees
  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 10

ImmunoMet General Information

Description

Developer of novel anti-tumor and immuno-oncology therapies designed to treat cancer patients. The company's therapies include oncology drugs and metabolic regulators to increase patient survival by disrupting cancer metabolism and enhancing anti-cancer immunity by targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells, enabling healthcare providers to provide long-term survival and quality of life for cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • JLABS at Texas Medical Center
  • 2450 Holcombe Boulevard
  • Houston, TX 77021
  • United States
+1 (346) 000-0000

ImmunoMet Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunoMet Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B1) 31-Dec-2021 0000 000.00 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series B) 05-Feb-2020 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 07-Mar-2017 000 000.00 0000 Completed Clinical Trials - General
3. Accelerator/Incubator 02-Mar-2016 00.00 Completed Startup
2. Early Stage VC (Series A) 05-Feb-2016 $5.2M $6.2M 000.00 Completed Startup
1. Seed Round 01-Aug-2015 $996K $996K 00.000 Completed Startup
To view ImmunoMet’s complete valuation and funding history, request access »

ImmunoMet Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00 00 00 00.000
Seed 800,000 $0.001000 $1.25 $1.25 1x $1.25 17.04%
To view ImmunoMet’s complete cap table history, request access »

ImmunoMet Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel anti-tumor and immuno-oncology therapies designed to treat cancer patients. The company's therapies i
Drug Discovery
Houston, TX
9 As of 2022
000.00
000000 - 000 000.00

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00000

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000000000000
Waltham, MA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmunoMet Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000 000000000000 Formerly VC-backed Waltham, MA 000 00000 00000000 00000
0000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

ImmunoMet Patents

ImmunoMet Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3871668-A1 Hair growth promoting composition comprising guanidine derivative Pending 14-Nov-2018 0000000000
JP-2022510570-A Hair growth promoting composition containing a guanidine derivative Pending 14-Nov-2018 0000000000 0
US-20220000811-A1 Composition for promoting hair growth comprising a guanine derivative Pending 14-Nov-2018 0000000000
US-20200038347-A1 Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same Inactive 24-Jan-2017 0000000000
US-20210113497-A1 Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same Pending 24-Jan-2017 A61K31/155
To view ImmunoMet’s complete patent history, request access »

ImmunoMet Executive Team (18)

Name Title Board Seat Contact Info
Benjamin Cowen Ph.D President, Chief Executive Officer & Board Member
Michael Bell Chief Financial Officer
Dean Welsch Ph.D Chief Scientific Officer
Jae-Ho Cheong MD Advisor
Russell Jones Ph.D Advisor
You’re viewing 5 of 18 executive team members. Get the full list »

ImmunoMet Board Members (10)

Name Representing Role Since
Andrew Kim Incon Company Board Member 000 0000
Benjamin Cowen Ph.D ImmunoMet President, Chief Executive Officer & Board Member 000 0000
Jae-Joon Kim Mirae Asset Venture Investment Board Member 000 0000
Paul Lammers MD Self Board Member 000 0000
Sean Jeong MD ImmunoMet Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

ImmunoMet Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunoMet Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Incon Company Corporation Minority 000 0000 000000 0
InterVest Venture Capital Minority 000 0000 000000 0
NHN Investment Venture Capital Minority 000 0000 000000 0
SL Investment Venture Capital Minority 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »